The traditional measure of therapeutic outcome A) MRI system 1 Strength of magnet High resolution is needed for accurate monitoring of MS since many plaques are small such as 2-5 mm diameter. At low fields (for example, 0-15T) a slice thickness of 10 mm is usually required to obtain satisfactory images in a reasonable time, whereas at 0-5T and above, good images are obtained with 5 mm thick slices.
Patients with secondary progressive MS have been studied serially at 01S5T1' and 05T.'0 At the lower field with 10 mm thick slices, 10/25 (40%) new lesions disappeared completely on follow, up scans, whereas only 7/109 (6%) new lesions disappeared at 0-5T using 5 mm thick slices. We therefore recommend that studies are performed on systems with a field strength of 0-5T or more. Serial examination of individual patients should be undertaken on the same scanner, as there is always some variation in image quality between scanners.
Repositioning
To detect changes on follow up scans with reliability, accurate repositioning of the patient is essential. The history of stereotaxy reminds us that if we want to be very precise, only fixation devices and stereotactic methods can be used. An alternative that will be widely available in the future will be the use of computer programs of volumetric display and reconstruction and orientation of slices. At present, the most suitable methods are ones which orientate around certain well visualised anatomical landmarks.'2 Whichever method is chosen, we recommend that it is the same for all centres involved in a multicentre trial. The following method has been used successfully in some of our units: the patient is placed in a comfortable manner within the head coil and moved to the scanning position within the magnet bore. A low resolution coronal pilot scan is performed, followed by a high resolution sagittal Tl-weighted scan to demonstrate the anterior and posterior commissures, which serve as the landmarks for the oblique orientation of the axial plane (parallel to the bicommisural line). Height adjustment is achieved by placing the middle slice over the inter-commissural line. Motion artefact can be reduced by using a head fixation device such as a velcro band.
gested that additional infratentorial lesions may be detected on sagittal images,"9 but there were a number of differences between the axial and sagittal protocols which favoured the latter. If all other parameters are constant, there is probably little difference in lesion detection with varying slice orientation. We recommend using an axial profile as this is the most widely accepted. Thompson (London) reported that enhancement in such lesions increased the overall detection of active lesions by 10%. Secondly, enhancing lesions have been observed in the cortex and subcortical white matter when they are not visible on unenhanced T2-weighted MRI'4 "8-detection of lesions in these regions is poor using standard T2-weighted sequences because of the longer T2 of normal cortex. Thirdly, Gd-DTPA enhancement frequently increases the conspicuousness of small new lesions and thereby confirms their sometimes equivocal appearance on a T2-weighted scan.
Tl-weighted SE sequences (for example, SE500/20 at 0-5T) are more sensitive than inversion recovery sequences in detecting enhancing MS lesions,'4 and should be used. Scanning should start at least five minutes after injection of Gd-DTPA, as most lesions display maximum enhancement five to 30 minutes post injection.'725 Images should be obtained at the same time post injection on all follow up scans.
Direct comparison of different doses of Gd-DTPA has not been studied for MS. With brain tumours, there is satisfactory enhancement with 0-1 mmol/kg, little additional enhancement with 0-2 mmol/kg, but appreciably less with 0 05 mmol/kg.26 We therefore recommend a dose of 0-1 mmol/kg, which should be injected over three minutes.
Minor side effects from Gd-DTPA, such as nausea and headache, are infrequently described.27 Extravascular injection produces local pain, and leads to tissue reaction in rats;28 we therefore recommend that injection is made either under direct observation outside of the scanner, or via a secure intravenous line with the patient in situ in the scannerthe latter approach has the advantage of identical positioning for the pre-and post-contrast sequences.
Anaphylactoid reactions have been described with Gd-DTPA,29 although with great rarity-probably of the order of one in 100 0003-and no fatal reactions have occurred. Appropriate resuscitation facilities should be available, but the currently reported low incidence of serious reactions does not preclude using Gd-DTPA in monitoring treatment trials in MS. Gd-DTPA should not be used in pregnancy.
Other gadolinium containing contrast agents (for example, Gd-DOTA, Gd(HP-DO3A)) probably have a similar efficacy as Gd-DTPA in terms of enhancement capability, although they have not been evaluated as extensively. It remains to be seen whether they will have even less frequent side effects.
To conclude, gadolinium enhancement should be used in monitoring treatment in patients with relapsing-remitting or secondary progressive MS (we do not recommend enhancement in patients with primary progressive MS-see section B). It increases the yield of active inflammatory lesions, improves their clarity, and is sufficiently well tolerated to allow serial administration. Vancouver) found that 36% of active lesions (that is, new or enlarging) were seen for less than four weeks. However, given the low sensitivity for small lesions at this field strength, it is possible that subtle changes which may have been apparent with monthly scans on a higher field system were missed. Thompson (London) performed fortnightly studies at 0-5T, and found that while Gd-DTPA enhancement persisted for less than four weeks in 25% of new lesions, such lesions invariably persisted on the unenhanced scan even though they were small, that is, they would have been detected as new lesions on the monthly unenhanced MRI. There is, of course, a much lower yield of enhancing lesions when the scanning interval is greater than one month.
Thus at 05T and above, fortnightly Gd-DTPA enhanced MRI detects few additional active lesions compared with monthly scanning. Our patients have complied well with monthly examinations for up to six months, and we consider that this is the most suitable interval for studies of such a duration.
In deciding the duration of a study, it is necessary to consider how much MRI activity will occur in a given period. Over a six month period, Thompson (London) identified a total of 172 active lesions (mean = 10; range 0-69) in 17 patients with early relapsing-remitting or a) The proportion of patients developing active lesions Eighty eight per cent of Thompson's patients developed one or more active lesions during the six months. Twenty one patients in both the active and placebo-treated groups would be needed to show a 50% reduction in this proportion (Chi-squared test; a error = 5%, f error = 10%).Eleven patients would be needed in each group to show a 70% reduction, and six would be needed to show a 90% effect.
b) The mean number ofactive lesions/patient In Thompson's patients, the number of active lesions/patient is not normally distributed (table) . We cannot therefore calculate a sample size based on differences in the mean. The log of the number of active lesions/patient is approximately normally distributed. If we use the mean of the log to measure outcome, 150 patients would be needed in both the active and placebo-treated arms of the study to show a 50% reduction (2 sample t test, a error = 5%, , error = 10%). Fifty patients would be needed in each group to demonstrate a 70% reduction, and 14 to show a 90% effect.
A third outcome which might be measured is the total number of active lesions that develop in both active and placebo-treated groups, but such data is non-parametric, and formulas do not exist for calculating case numbers. A fourth outcome would be the change in total lesion area/volume, but this will probably be unsuitable for a study duration of only six months (see section D3).
The case numbers calculated are not intended to be used as definitive guidelines for treatment trials, based as they are on serial data from only 17 untreated patients; clearly, further natural history studies are needed to consolidate this data. Nevertheless, two observations can be made. First, whatever outcome is measured, a highly effective treatment (90%) is likely to produce significant results with small patient numbers. Secondly, when measuring outcome as the mean number of active lesions, substantial patient numbers will be needed to detect a moderate (50%) treatment effect, due to the very large interpatient variation in the number of active MRI lesions (table) .
If over time there was less variation in MRI activity within the same patient than there was between patients, it should be possible to demonstrate treatment effect with smaller numbers, by using patients as their own control, that is, having a period of MRI monitoring before the start of treatment. In Thompson's patients, although there appears to be some consistency within patients over time, using patients as their own control did not result in a reduction in sample size.
Summary
In a randomised controlled study, a useful treatment effect should be observed after six months of monthly gadolinium enhanced scanning, whereas clinical monitoring generally requires at least two years of follow up.' This early indication of efficacy should be obtained from a small number of patients when the treatment is highly effective. Because the amount of MRI activity varies considerably both between and within patients over time, more substantial numbers may be required to demonstrate less marked but nevertheless useful treatment effects; in this context, multicentre studies will be essential, which underlies the need for a common protocol and database, such as those being developed by Concerted Action on Multiple Sclerosis under the auspices of the CEC. Such short duration MRI studies will influence the decision to proceed with longer term clinical trials. At each follow up scan, the number of new, enlarging and enhancing lesions should be recorded. In the case of multicentre studies, this analysis should be performed at a single, common centre, by two experienced neuroradiologists.
The minimal size requirement for a lesion is 3 pixels. On unenhanced T2-weighted scans, a lesion should be visible on both echos, although it may be more conspicuous on one. Enhancement should only be recorded when a lesion displays hyperintensity compared with surrounding brain parenchyma on a Tiweighted sequence (Tl-weighted pre-contrast images are not necessary). 3 Quantitative analysis of scans Lesion area/volume measurement Crude estimates of lesion size can be obtained by measuring its largest diameter.6 Semiautomated measurement of lesion size is obtained by an observer using a computer assisted tracking method. The intra-rater variability of the technique, however, varies from five to 20% (Paty, Vancouver; Berry, Toulouse; Wicks, London), depending on the degree of experience of the observer. Interrater variability is even higher, and the technique is extremely time consuming. More fully automated techniques have been developed,"' but none is completely satisfactory; for example, thresholds set to exclude normal grey matter will miss white matter lesions with a T2 between that of cortex and white matter.
Consideration of the natural history of MS suggests limitations in using lesion area/ volume measurements to monitor MS in the short term. First, new lesions wax and wane in size, and thus the total lesion area/volume fluctuates with time, rather than increasing in a steady fashion. Secondly, given the lengthy duration of MS, the increases in stable lesion area/volume which occur over a brief study period (such as, six months) will often fall within the margin of error of the measurements. 
